stockrowMediWound Ltd.
MDWDMediWound Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.0 million, down 16.1% from fiscal 2024.
- Revenue
- −45.8%
- EPS
- +53.7%
- Free cash flow
- −49.9%
- Total debt
- +51.8%
Quarter to June 2026, against a year earlier
Follow MDWD
Alert me
MediWound Ltd. (MDWD) EV/Sales
As of 6 November 2026, MediWound Ltd. (MDWD) trades at a EV/Sales of 12.6×. Over the past ten years it has ranged from −14.0× (December 2016) to 427× (January 2015); the current reading is higher than 84% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 9.3× | 39.60% |
| FY2024 | 6.7× | 101.38% |
| FY2023 | 3.3× | 166.36% |
| FY2022 | 1.2× | — |
| FY2021 | −0.1× | — |
| FY2020 | −0.3× | — |
| FY2019 | −0.5× | — |
| FY2018 | −2.3× | — |
| FY2017 | −8.3× | — |
| FY2016 | −8.7× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 13.1× | 15.56% |
| Mar 2026 | 11.3× | 21.53% |
| Dec 2025 | 9.3× | 38.50% |
| Sep 2025 | 6.7× | (25.18%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| UPB Upstream Bio, Inc. compare | −26.9× |
| BCYC Bicycle Therapeutics PLC Sponsored ADR compare | −2.3× |
| BBOT BridgeBio Oncology Therapeutics, Inc compare | n/m |
| IVVD Invivyd, Inc. compare | 0.3× |
| CGEN Compugen Ltd. compare | 0.8× |
| WHWK Whitehawk Therapeutics, Inc. compare | 2.5× |
| TRDA Entrada Therapeutics, Inc. compare | 3.6× |
| ACOG Alpha Cognition Inc. compare | 9.2× |
| MDWD MediWound Ltd. | 12.6× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)